Gossamer Bio, Inc.
Gossamer Bio, Inc. is listed today as Gossamer Bio, Inc.: market value, financials and filings are on its company page.
Funding rounds
2 counted as startup funding, 3 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Aug 2026 | $25 M | Private placement after listing | $10 to $50 million | options | SEC | |
| Jul 2023 | $212 M | Private placement after listing | $50 to $250 million | equity, options | SEC | |
| Jul 2022 | $120 M | Private placement after listing | $50 to $250 million | equity | SEC | |
| Jul 2018 | $230 M | No. 2 | $50 to $250 million | equity | SEC | |
| Jan 2018 | $70 M | No. 1 | $50 to $250 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Gossamer Bio, Inc., its revenue in fiscal 2025 came from these product and service lines: Revenue from contracts with collaborators $48.47 million (100%).
Annual report (SEC XBRL) · Dec 2025
Gossamer Bio, Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2026).
SEC Form D · Sep 2026
The industry group it chose in its notices: Biotechnology.
SEC Form D · Sep 2026
Products and services#
No products or services of Gossamer Bio, Inc. are on record.
Investors#
9 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| ARCH Venture Fund IX, L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| ARCH Venture Fund IX Overage, L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| ARCH Venture Partners IX, LLC | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| ARCH Venture Partners IX, L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| ARCH Venture Partners IX Overage, L.P. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Bryan Giraudo | Person | not stated | not stated | Held Series A and B preferred stock (Form 3, 2019) | SEC Form 3 |
| Omega Fund V GP, L.P. | Fund or asset manager | not stated | not stated | Held Series Seed, A and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Omega Fund V GP Manager, Ltd. | Fund or asset manager | not stated | not stated | Held Series Seed, A and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Omega Fund V, L.P. | Fund or asset manager | not stated | not stated | Held Series Seed, A and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 67 investors.
Largest shareholders today
Institutions holding Gossamer Bio, Inc. shares, as of Sep 30, 2026.
- 683 Capital Management, LLC$6 M8.01%
- Opaleye Management Inc.$5 M6.98%
- Context Capital Management, LLC$4 M5.92%
- D. E. Shaw & Co., Inc.$4 M4.98%
- FMR LLC$3 M4.76%
- SummitTX Capital, L.P.$2 M2.98%
- Vanguard Capital Management LLC$2 M2.63%
- Kalehua Capital Management LLC$2 M2.28%
- BlackRock, Inc.$1 M1.76%
- ARCH Venture Management, LLC$1 M1.65%
- Marshall Wace, LLP$1 M1.63%
- Samsara Biocapital, LLC$1 M1.44%
- Corient Private Wealth LP$1 M1.36%
- Highbridge Capital Management LLC$1 M1.24%
- Geode Capital Management, LLC$1 M1.15%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Bryan D. Giraudo | Executive officer | Sep 2026 |
| Caryn D. Peterson | Executive officer | Sep 2026 |
| Christian D. Waage | Executive officer | Sep 2026 |
| Faheem Hasnain | Executive officer | Sep 2026 |
| Robert D. Smith | Executive officer | Sep 2026 |
| Bryan Giraudo | Executive officer | Aug 2023 |
| Caryn Peterson | Executive officer | Aug 2023 |
| Christian Waage | Executive officer | Aug 2023 |
| Richard Aranda, M.D. | Executive officer | Aug 2023 |
| Laura Carter, Ph.D. | Executive officer | Jul 2022 |
| Jill Howe | Executive officer | Aug 2018 |
| Sheila Gujrathi, M.D. | Executive officer | Aug 2018 |
| Faheem Hasnain | Director | Sep 2026 |
| John D. Quisel | Director | Sep 2026 |
| Russell Cox | Director | Sep 2026 |
| Sandra J. Milligan | Director | Sep 2026 |
| Skye J. Drynan | Director | Sep 2026 |
| Steven D. Nathan | Director | Sep 2026 |
| Thomas Daniel | Director | Sep 2026 |
| Kristina Burow | Director | Aug 2023 |
| Renee Gala | Director | Aug 2023 |
| Sandra Milligan, M.D., J.D. | Director | Aug 2023 |
| Thomas Daniel, M.D. | Director | Aug 2023 |
| Joshua Bilenker, M.D. | Director | Jul 2022 |
| Michael Yi | Director | Aug 2018 |
| Otello Stampacchia, Ph.D. | Director | Aug 2018 |
| Richard Lim | Director | Aug 2018 |
| Robert Nelsen | Director | Aug 2018 |
| Sheila Gujrathi, M.D. | Director | Aug 2018 |
Went public since 2019. Its SEC number is that of a company listed on a stock exchange.